Most endometrial cancer is driven by a single, well-understood mechanism: too much estrogen stimulating the uterine lining without enough progesterone to counterbalance it. That means many of the most effective prevention strategies come down to reducing estrogen exposure, and several of them are lifestyle changes you can start today. Maintaining a healthy weight is the single most impactful step, but exercise, reproductive choices, and even coffee consumption also play measurable roles.
Why Estrogen Exposure Is the Central Risk
The lining of the uterus grows in response to estrogen. Progesterone normally acts as a brake, triggering the lining to shed each month during menstruation. When estrogen goes unopposed, either because ovulation isn’t happening regularly, because of hormone therapy after menopause, or because fat tissue is producing extra estrogen, the lining keeps thickening. Over time, that persistent stimulation can progress from thickening (hyperplasia) to precancerous changes to cancer.
Nearly every major risk factor for endometrial cancer traces back to this imbalance. Obesity, irregular ovulation from conditions like polycystic ovary syndrome (PCOS), estrogen-only hormone therapy, and never having been pregnant all increase the total amount of unopposed estrogen your body is exposed to over a lifetime. Prevention, then, is largely about tipping that balance back.
Keep Your Weight in a Healthy Range
Excess body fat is the strongest modifiable risk factor for endometrial cancer. Fat tissue converts other hormones into estrogen, so the more fat you carry, the more estrogen circulates in your body. A pooled analysis of over 12,000 women found that every 5-point increase in BMI raised endometrial cancer risk by about 63%. The relationship isn’t a straight line, either. At higher BMIs, the risk climbs faster, meaning the difference between a BMI of 35 and 40 matters more than the difference between 25 and 30.
If you’re currently overweight, even modest weight loss can meaningfully shift the equation. Losing weight reduces circulating estrogen levels, improves insulin sensitivity, and lowers chronic inflammation, all of which contribute to a healthier uterine lining.
Exercise at Least 150 Minutes Per Week
Regular physical activity reduces endometrial cancer risk independent of its effect on weight. A study from the Yale School of Public Health found that women who exercised at least 150 minutes per week had a 34% lower risk of endometrial cancer compared to sedentary women. The exercise didn’t need to be intense. Moderate-paced walking counted, along with activities like yoga, swimming, and tennis.
Exercise lowers circulating estrogen and insulin levels directly, which likely explains the benefit beyond weight control alone. The 150-minute threshold aligns with general physical activity guidelines, so meeting the standard recommendation for heart health also protects your uterus.
Oral Contraceptives Offer Lasting Protection
Combined birth control pills (containing both estrogen and a progestin) reduce endometrial cancer risk by at least 30%, and the protection increases with longer use. The progestin component regularly opposes estrogen’s effect on the uterine lining, preventing the kind of unchecked buildup that leads to cancer. This protective effect persists for years after you stop taking the pill.
For women with PCOS, oral contraceptives serve double duty. PCOS causes irregular or absent ovulation, which means months can pass without the progesterone surge that normally triggers a period. The uterine lining keeps growing under estrogen’s influence. Birth control pills restore that hormonal cycling. For women with PCOS who aren’t on the pill, doctors sometimes prescribe a progestin to take for 10 to 14 days each month, ensuring the lining sheds regularly.
Manage Hormone Therapy Carefully After Menopause
Estrogen-only hormone therapy dramatically increases endometrial cancer risk. Women who take it for 10 or more years face roughly 4.5 times the risk of women who never used hormone therapy. If you still have a uterus and need hormone therapy for menopausal symptoms, taking a progestin alongside estrogen is essential. Combined therapy with adequate progestin actually reduces endometrial cancer risk by about 35% compared to never using hormones at all, because the progestin keeps the lining from building up.
Not all combined regimens are equal, though. “Sequential” regimens that include fewer than 10 days of progestin per month still carried a significantly elevated risk after 10 years of use (about 4.4 times higher), nearly matching estrogen-only therapy. Continuous combined therapy, where progestin is taken every day, performed better but still showed a roughly doubled risk after a decade, particularly in thinner women. If you’re using hormone therapy long-term, the type, dose, and schedule of progestin all matter.
Pregnancy and Breastfeeding Lower Risk
Each full-term pregnancy reduces endometrial cancer risk. During pregnancy, progesterone levels are very high and estrogen’s effect on the uterine lining is suppressed. Women who have never been pregnant miss out on these long stretches of progesterone dominance, which is one reason nulliparity is a recognized risk factor.
Breastfeeding adds further protection. A large analysis of over 26,000 women found that breastfeeding for more than three months per child was associated with a statistically significant reduction in endometrial cancer risk. The benefit grew with longer total breastfeeding duration, with women who breastfed for more than 36 months total across all children seeing a 33% reduction in risk. Per child, the sweet spot appeared to be around 6 to 9 months of breastfeeding, after which additional months added less incremental benefit.
Coffee Consumption at Higher Amounts
Women who drink four or more cups of coffee per day have about 25% lower endometrial cancer risk compared to women who drink less than one cup daily. This finding comes from a 26-year prospective study tracking tens of thousands of women, and the association held after adjusting for weight, smoking, and other factors. Fewer than four cups per day showed no meaningful benefit.
Coffee lowers circulating estrogen and insulin levels, which likely explains the connection. The benefit appeared strongest among postmenopausal women, women with obesity, and women not using hormone therapy. Caffeinated coffee showed a slightly stronger association than decaffeinated, and tea had no effect at all. Adding large amounts of sugar and cream could offset any benefit, so how you drink your coffee matters too.
Lynch Syndrome Requires a Specific Approach
Women with Lynch syndrome, an inherited condition that sharply increases the risk of several cancers, face a 40 to 60% lifetime risk of endometrial cancer. That’s as high as or higher than their already elevated risk of colon cancer. The median age at diagnosis is just 46.
For these women, preventive removal of the uterus and ovaries after childbearing is the most effective strategy available. In a study published in the New England Journal of Medicine, not a single woman who underwent preventive surgery developed endometrial cancer, compared to a 33% cancer rate in the control group. That amounts to a 100% prevented fraction. Three women who had the surgery were found to already have early, undetected endometrial cancer at the time of the procedure, underscoring how silently the disease can develop in this population. Current guidance supports considering surgery after age 35 or once childbearing is complete.
Diabetes, Insulin, and Blood Sugar Control
Type 2 diabetes and insulin resistance are independent risk factors for endometrial cancer, beyond their connection to obesity. High insulin levels stimulate cell growth in the uterine lining, and elevated blood sugar creates an environment that favors cancer development. Better blood sugar control is associated with lower endometrial cancer risk, even among women who remain overweight.
The diabetes medication metformin has drawn significant research interest because it lowers blood sugar, improves insulin sensitivity, and is associated with modest weight loss. Some studies suggest metformin users have lower rates of endometrial cancer, and a meta-analysis found that diabetic patients using metformin had about half the all-cause mortality of diabetic patients not taking it across several cancer types, including endometrial. The evidence is still mixed and limited by small studies, but for women already taking metformin for diabetes, the potential cancer benefit is a reasonable bonus rather than a reason to start the drug on its own.